Positively Aware Triumeq


dolutegravir, abacavir, lamivudine DTG, (INSTI); ABC, 3TC (two NRTIs)

DHHS recommended initial regimen for most people if HLA-B*5701 negative
Single-Tablet Regimen

Standard Dose

One tablet once daily, with or without food, for people with no evidence of INSTI resistance. An additional 50 mg dose of dolutegravir (brand name Tivicay) separated by 12 hours from Triumeq is required for people who have INSTI drug resistance or are taking certain other medications.

For adults and children. Triumeq PD, which are tablets that are dissolved in 20 ml of water and taken within 30 minutes of mixing, are for pediatric patients 22–55 pounds (10–25 kg). Triumeq PD is not interchangeable with the adult formulation. Therefore, adults should not take the pediatric formulation. Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Dose cannot be adjusted for people with kidney or liver problems. According to the drug label, Triumeq is not recommended for people who have decreased kidney function (creatinine clearance less than 30 mL/min) due to lamivudine component, or those with mild, moderate, or severe liver impairment due to abacavir component. This medication combination, however, is often used in reduced renal function below 30 mL/min, due to relatively minimal risk of lamivudine accumulation and side effects. In addition, alternative doses may be obtained by using the individual components of this medication as needed.
  • See the individual drugs contained in Triumeq: Tivicay, Ziagen, and Epivir.
  • See package insert for more complete information on potential side effects and interactions.


ViiV Healthcare
viivhealthcare.com; triumeq.com
(877) 844-8872



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments